| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | ZocDoc | Healthcare Digital Health | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $102.00K | -- | 1 | -- | $5.00 | +0.00% | +0.00% | $1.15B | Series D-2 | 2/11/2021 | $100M | $2.62B | $29.29 | Francisco Partners | ||||
 | Included Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $529.32M | Series E | 9/9/2020 | $103.04M | $1.13B | $3.22 | The Carlyle Group | ||||
 | Precision Neuroscience | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $1.84M | -- | 5 | Not available | -- | -- | $466.59M | Series D | 9/11/2026 | $287.5M | $1.04B | $7.20 | Undisclosed Investors | ||||
 | Collective Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $3.2M | -- | 1 | $0.16 | -11.11% | -20.00% | $713.28M | Series F | 5/4/2021 | $280M | $1.53B | $0.75 | HCSC, DFJ Growth, Founders Fund, G Squared, Maverick Ventures, NEA, PFM Health Sciences, SoftBank, Sun Life Financial | ||||
 | Midi Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $251.97M | Series D | 2/3/2026 | $100M | $1B | $10.06 | Goodwater Capital, Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens, McKesson Ventures, Felicis | ||||
 | Function Health | Healthcare Digital Health | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $521.18M | Series B-2 | 7/30/2026 | $94.11M | $2.94B | $92.23 | Undisclosed Investors | ||||
 | Cityblock Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | $15.38 | -0.90% | -15.86% | $1.83B | Series X | 6/18/2024 | $39M | $1.58B | $19.91 | Undisclosed Investors | ||||
 | Hippocratic AI | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $402.92M | Series C | 11/3/2025 | $126M | $3.5B | $26.33 | Avenir Growth, CapitalG, General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest, Universal Health Services, Cincinnati Children's Hospital, WellSpan Health, John Doerr, Rick Klausner | ||||
 | Enveda | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $807.14M | Series E | 9/9/2026 | $311M | $1.61B | $10.38 | Undisclosed Investors | ||||
 | Honor | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $644.41M | Series E | 10/5/2021 | $70M | $1.25B | $3.16 | Baillie Gifford, T. Rowe Price Associates, Prosus Ventures, FMZ Ventures, Rock Springs Capital, TriplePoint Capital, Thrive Capital | ||||
 | Sword Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $540.19M | Junior | 1/16/2026 | $175.33M | $4.15B | $71.51 | Undisclosed Investors | ||||
 | Innovaccer | Healthcare Healthcare Software | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | $2.62 | +9.62% | -20.61% | $653.62M | Series F-1 | 1/9/2025 | $153.04M | $3.45B | $7.39 | B Capital Group, Banner Health, Danaher Ventures, Generation IM, Kaiser Permanente, M12 | ||||
 | Maven | Healthcare Digital Health | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.48B | Series F | 8/16/2024 | $125M | $1.7B | $17.77 | StepStone Group, General Catalyst, Sequoia Capital, Oak HC/FT, Icon Ventures, Dragoneer Investment Group, Lux Capital | ||||
 | NewLimit | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $682.09M | Series C-2 | 6/2/2026 | $210M | $3.1B | $53.47 | Founders Fund, Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, NFDG, Valor Equity Partners, Lilly Ventures, Human Capital | ||||
 | Chai Discovery | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $100.13K | -- | 1 | -- | Not available | -- | -- | $620.17M | Series C | 7/14/2026 | $400M | $3.8B | $178.05 | Index Ventures, Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, Yosemite, Scribble Ventures | ||||
 | Insitro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.26B | Series C | 3/15/2021 | $400M | $2.57B | $18.29 | CPP Investments, Andreessen Horowitz, T. Rowe Price, Casdin Capital, BlackRock, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital, Alexandria Venture Investments, Temasek, Softbank | ||||
 | Komodo Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $587.08M | Series F | 3/31/2025 | $50M | $3.71B | $51.00 | Undisclosed Investors | ||||
 | Owkin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $279.77M | Series B-1 | 6/8/2022 | $50M | $1.46B | $45.70 | Bristol Myers Squibb | ||||
 | Pathos | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $732M | Series E | 8/21/2026 | $300M | $2.97B | $13.24 | Undisclosed Investors | ||||
 | ArsenalBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $2.44B | Series C | 9/4/2024 | $327.5M | $1.66B | $18.58 | ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVIDIA, Luma Group, T. Rowe Price Associates, Rock Springs Capital, Parker Institute for Cancer Immunotherapy, SoftBank, Bristol-Myers Squibb, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, Hitachi Ventures | ||||
 | Rula | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $3.8M | -- | 1 | Not available | -- | -- | $268.55M | Series C-1 | 2/17/2026 | $6.24M | $2.4B | $11.32 | Undisclosed Investors | ||||
 | Ambience Healthcare | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $302.59M | Series C | 7/29/2025 | $210M | $1.24B | $37.98 | Oak HC/FT, Andreessen Horowitz, OpenAI, Kleiner Perkins, Optum Ventures, Frist Cressey Ventures, Town Hall Ventures, Smash Capital, Georgian, Founders Circle Capital | ||||
 | Freenome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.35B | Series F | 2/15/2024 | $263.96M | $2.05B | $7.40 | Roche, Andreessen Horowitz, BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates | ||||
 | Generate Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $812.92M | Series C | 1/21/2025 | $399.4M | $2.22B | $11.85 | Amgen, Nvidia, MAPS Capital, Pictet Alternative Advisors, Flagship Pioneering, Abu Dhabi Investment Authority, Fidelity, T. Rowe Price, ARCH Venture Partners, March Capital, Alaska Permanent Fund, Altitude Life Science Ventures, Novartis | ||||